Threshold Retinopathy of Prematurity with Persistent Corneal Defect

2019 ◽  
Vol 33 (1-4) ◽  
pp. 29-31
Author(s):  
Shilpi H. Narnaware ◽  
Prashant K. Bawankule
Keyword(s):  
Case Report ◽  
Birth Weight ◽  
Retinopathy Of Prematurity ◽  
Early Treatment ◽  
Rescue Therapy ◽  
Intravitreal Ranibizumab ◽  
Systemic Problems ◽  
Underlying Pathology

Aim: A case which highlights the challenges faced in treating a case of type 1 early treatment of retinopathy of prematurity (ETROP) with persistent corneal defect. Case Report: We report a case of a preterm boy born at 28 weeks with birth weight of 700 g who presented with persistent corneal defect along with type 1 ETROP disease. Because of the inability to complete LASER, intravitreal ranibizumab was given as a rescue therapy to buy some time. But unfortunately, baby succumbed to disease because of associated systemic problems. Conclusion: ROP can present with persistent corneal defect which can challenge the treatment of underlying pathology.

scholarly journals Different retinopathy of prematurity severity and outcomes in triplets: A case report

2020 ◽  
Vol 8 ◽  
pp. 2050313X2094430
Author(s):  
Ashwaq Bin Amro ◽  
Rawdha Alnuaimi ◽  
Tin Chan ◽  
Abeer Alali
Keyword(s):  
Case Report ◽  
Weight Gain ◽  
Birth Weight ◽  
Diode Laser ◽  
Gestational Age ◽  
Retinopathy Of Prematurity ◽  
Spherical Equivalent ◽  
Intravitreal Ranibizumab ◽  
The Right

In this case report, we discuss the presentation of retinopathy of prematurity in triplets born at 25 + 3 weeks gestational age of whom each had a different birth weight, weight gain and treatment requirements. Triplet A weighed 800 g and his retinopathy of prematurity had resolved with no intervention. Triplet B weighed 630 g at birth and he required bilateral intravitreal ranibizumab injection at 32 + 6 weeks. Triplet C weighed 520 g and required bilateral intravitreal ranibizumab injection at 36 weeks, but after 5 weeks he had recurrence which was treated with bilateral diode laser. Triplet C had the poorest weight gain. The main differences between the triplets are the birth weight and the weight gain. Furthermore, refraction was performed at 10 months; triplet A had a hyperopia of +1.25 spherical equivalent in both eyes, triplet B had mild myopia of −0.25 spherical equivalent and triplet C had a myopia of −3.00 spherical equivalent in the right eye and −2.75 spherical equivalent in the left eye.

scholarly journals Asymmetric Outcomes of Type 1 Retinopathy of Prematurity after Bilateral Intravitreal Ranibizumab Treatment

2017 ◽  
Vol 2017 ◽  
pp. 1-8
Author(s):  
Qiujing Huang ◽  
Qi Zhang ◽  
Yu Xu ◽  
Xunda Ji ◽  
Ping Fei ◽  
...  
Keyword(s):  
Retinal Detachment ◽  
Retinopathy Of Prematurity ◽  
Vitreous Hemorrhage ◽  
High Rate ◽  
Intravitreal Ranibizumab ◽  
Outcome Group ◽  
Significant Difference ◽  
Type 1 Rop ◽  
Ranibizumab Treatment

Purpose. To present cases with retinopathy of prematurity (ROP), who were treated with intravitreal injection of ranibizumab (IVR) and had unpredictable asymmetric outcomes. Methods. A retrospective review was performed in infants with type 1 ROP and had bilateral IVR (0.25 mg/0.025 mL) as initial treatment. Patients were classified into the asymmetric outcome group and the symmetric outcome group. Results. Eighty-four patients (168 eyes) were included. There were 18 eyes of 9 patients (10.7%) in the asymmetric outcome group and 150 eyes of 75 patients (89.3%) in the symmetric outcome group. In the symmetric outcome group, 86 eyes (57.3%) had ROP regression, 60 eyes (40%) had reactivation requiring laser treatment, and 4 eyes (2.7%) progressed to retinal detachment requiring vitrectomy. In the asymmetric outcome group, one of the eyes of the 9 patients had ROP regression with/without reactivation after IVR, while the contralateral eyes had negative response, including remarkable posterior fibrosis, partial or total retinal detachment, and vitreous hemorrhage. There was statistically significant difference between the birth weight of the two groups. Conclusion. Contralateral eyes with ROP can take a different clinical course after ranibizumab treatment. High rate of reactivation after IVR is another concern that ophthalmologists should pay attention to.

scholarly journals Diagnosis and the importance of early treatment of tyrosinemia type 1: A case report

2019 ◽  
Vol 12 ◽  
pp. 1-6
Author(s):  
Ana Škaričić ◽  
Marija Zekušić ◽  
Ksenija Fumić ◽  
Dunja Rogić ◽  
Valentina Uroić ◽  
...  
Keyword(s):  
Case Report ◽  
Early Treatment ◽  
Tyrosinemia Type 1

scholarly journals Screening Retinopathy of Prematurity in Extremely Low Birth Weight Infants in China and the Need for Earlier Screening Times

2016 ◽  
Vol 2016 ◽  
pp. 1-4 ◽  
Author(s):  
Jianxun Wang ◽  
Feng Chen ◽  
Shiping He ◽  
Daoman Xiang
Keyword(s):  
Birth Weight ◽  
Low Birth Weight ◽  
Retinopathy Of Prematurity ◽  
Age Of Onset ◽  
Screening Strategy ◽  
Extremely Low Birth Weight ◽  
Low Birth Weight Infants ◽  
Group A ◽  
The Mean

Purpose. To convey the need for a revised screening strategy for retinopathy of prematurity (ROP) for extremely low birth weight (ELBW) infants in China.Design. A retrospective longitudinal study.Methods. The medical charts of infants with a birth weight (BW) of less than 1 kg were reviewed. The infants were divided into three groups: group A, without ROP; group B, with ROP but not up to type 1 prethreshold or threshold ROP; group C, with type 1 prethreshold or threshold ROP. Data collected included gender, gestational age (GA), BW, postmenstrual age (PMA), age of onset of ROP, and age at which treatment was carried out, if required.Results. A total of 77 infants were involved. Fifty-six infants developed ROP at any stage and 38 infants developed type 1 prethreshold or threshold ROP. The mean BW and GA of infants in group A were significantly different compared with groups B and C. The mean PMA of onset of ROP in infants who developed mild ROP was 37 weeks compared with 34 weeks for infants who developed severe ROP.Conclusion. ELBW infants have a higher incidence of ROP in China which highlights the need for optimizing neonatal care for these infants. In ELBW infants, ROP tends to develop more severely when it occurs earlier. It is necessary for ELBW infants, especially for those with a BW less than 800 g or a GA less than 25 weeks, to be initially screened at an earlier time.

scholarly journals Asymmetric response to ranibizumab in mixed choroidal neovascularization in a neovascular age-related macular degeneration diagnosed on OCT angiography – case report

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Martin Pencak ◽  
Miroslav Veith
Keyword(s):  
Optical Coherence Tomography ◽  
Case Report ◽  
Macular Degeneration ◽  
Age Related Macular Degeneration ◽  
Optical Coherence ◽  
Intravitreal Ranibizumab ◽  
Asymmetric Response ◽  
Age Related

Abstract Background To present a case report of a patient with a mixed choroidal neovascular membrane (CNV) with an asymmetric response to ranibizumab diagnosed on optical coherence tomography angiography (OCTa). Case presentation A 61-year-old male was referred to our department in September 2017 due to decreased vision in his left eye. Best-corrected visual acuity (BCVA) was 43 Early Treatment Diabetic Retinopathy Study (ETDRS) letters in the left eye. Macular edema was present in the left eye, and a mixed CNV was identified on the OCTa. Therapy with intravitreal ranibizumab was commenced. After 5 ranibizumab injections, the BCVA was 42 ETDRS letters, and considerable intraretinal edema was still present. OCTa showed a resolution of the type 2 lesion of the mixed CNV; however, the type 1 lesion had continued to grow. The patient was then switched to intravitreal aflibercept. After 3 monthly aflibercept injections, the BCVA improved to 53 ETDRS letters, and a reduction of the edema was observed on the optical coherence tomography (OCT). OCTa showed a decrease in both the area and vessel density in the type 1 lesion of the CNV. Therapy with aflibercept was continued; however, while the intraretinal edema continued to improve, atrophy developed in the macula and the BCVA worsened to 43 ETDRS letters. Conclusions Ranibizumab nonresponse in a neovascular age-related macular degeneration is not uncommon. However, to our knowledge, this is the first described case of an asymmetric response to ranibizumab in a mixed CNV. While the type 2 lesion of the CNV reacted swiftly to the ranibizumab therapy, the type 1 lesion continued to grow. As with some other cases of ranibizumab resistance, switching to aflibercept proved effective.

scholarly journals Intravitreal Ranibizumab and Laser Photocoagulation in the Management of Idiopathic Juxtafoveolar Retinal Telangiectasia Type 1: A Case Report

2012 ◽  
Vol 3 (3) ◽  
pp. 298-303 ◽  
Author(s):  
Angela Ciarnella ◽  
Sara Verrilli ◽  
Vito Fenicia ◽  
Cristina Mannino ◽  
Alessandro Cutini ◽  
...  
Keyword(s):  
Case Report ◽  
Laser Photocoagulation ◽  
Intravitreal Ranibizumab ◽  
Retinal Telangiectasia
Sign in / Sign up

Export Citation Format

Share Document